ABSTRACT
Background: Posttraumatic stress disorder (PTSD) is a debilitating psychiatric disorder which
develops in approximately 10% of trauma-exposed individuals. Currently, there are few early
preventive interventions available for PTSD. Intranasal oxytocin administration early posttrauma
may prevent PTSD symptom development, as oxytocin administration was previously
found to beneficially impact neurobiological (e.g. amygdala reactivity) and socio-emotional
PTSD vulnerability factors.